Legacy Financial Advisors Inc. Purchases 69 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Legacy Financial Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 878 shares of the biopharmaceutical company’s stock after buying an additional 69 shares during the period. Legacy Financial Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $923,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Truist Financial restated a “buy” rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Argus boosted their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,145.03 on Friday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The stock has a market capitalization of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The stock’s 50-day moving average price is $1,131.75 and its 200-day moving average price is $1,031.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.79 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock valued at $11,498,705 in the last three months. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.